Research
Hormonal
Lorcaserin's high selectivity for the 5-HT2C receptor minimizes the risk of valvulopathy and pulmonary hypertension seen with non-selective serotonergic drugs like fenfluramine.
Lorcaserin is designed to target weight loss pathways specifically, avoiding the heart valve receptors that caused problems with older drugs. Clinical data shows it does not significantly increase the risk of heart valve problems.
GoodSupportsHIGH confidence
Lorcaserin activates 5-HT2C with 18-fold selectivity over 5-HT2A and 104-fold selectivity over 5-HT2B... This preclinical profile suggests that lorcaserin should not cause valvulopathy or psychiatric side effects because of its high 5-HT2C selectivity.
Why this rating
Strong preclinical data and consistent clinical trial results showing no significant increase in valvulopathy compared to placebo.
Source
Modern Obesity Pharmacotherapy: Weighing Cardiovascular Risk and Benefit
Jonathan W. Cunningham et al. · Clinical Cardiology · 2014
DOI 10.1002/clc.22304
narrative_reviewCited 36×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Sympathomimetic obesity drugs (phentermine/topiramate, bupropion/naltrexone) increase heart rate and blood pressure, posing a potential cardiovascular risk despite weight loss benefits.Good
- Modern obesity pharmacotherapies (phentermine/topiramate, lorcaserin, bupropion/naltrexone) improve cardiovascular risk factors (blood pressure, lipids, glucose) but their impact on actual cardiovascular events and mortality remains unproven and requires dedicated outcomes trials.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →